DS Research was proud to be a participating site in the pivotal clinical trials that led to the FDA approval of Leqselvi™ (deuruxolitinib) for adults with severe alopecia areata. The drug was studied in two large Phase 3 trials—THRIVE-AA1 and THRIVE-AA2—which enrolled over 1,200 patients experiencing significant scalp hair loss. In these trials, participants received 8 mg or 12 mg of Leqselvi twice daily for 24 weeks. The results were compelling: more than 30% of patients achieved ≥80% scalp hair regrowth, with some reaching even higher levels of recovery. Leqselvi is a selective JAK1/JAK2 inhibitor, targeting immune pathways responsible for attacking hair follicles in alopecia areata. It is now an FDA-approved, oral treatment option for adults with severe forms of the disease.